Kay G. Balster

Principal / Authorized signatory

Kay Balster is one of High-Tech Gründerfonds’s longest-serving employees. Since 2009 he has been focusing on financing start-ups from the biotechnology and medical technology sectors. He can draw on 20 years of experience in advising technology start-ups, while his background in economics, training as a banker and especially the day-to-day interaction he has with the founders in his HTGF portfolio help him in his role.

When he is not working, family time and sport are his top priorities.

Portfolio

Exit

Posts & mentions

Press

1. August 2023

Bind-X secures €10 million in financing as part of its Series B financing round

Specialist in biological binding of materials expands internationally and prepares further market entries in agriculture, mining, and infrastructure. Martinsried, 1st of August 2023 – Bind-X, a fast-growing industrial biotechnology company, has successfully closed a €10 million financing round. The funding was provided by renowned investors from Germany and abroad (HG Ventures, K&K 1, Greeneering Invest, Saxovent) and will help drive the decarbonization and biologization of es

Press

12. January 2022

CereGate, the preeminent Computer-Brain-Interface Software Platform, advances in clinical development and secures financing from leading deep tech and mental health investors 468 Capital and re.Mind Capital

In the thriving field of neuroscience, CereGate is poised to revolutionize the treatment of neurological disorders by interacting with the human brain through a unique software-first approach. After making strides in the clinical development, including FDA Breakthrough designation for its first application in Deep Brain Stimulation Freezing of Gait Therapy (FOG-LIGHTS) and launching a clinical trial in the US, CereGate achieves additional funding to further accelerate the development of n